THIS week the National Institute for Clinical Excellence has approved oseltamivir (Tamiflu) for the prophylaxis of influencza in "at risk" patients. NICE recommends that when the influenza A or influenza B virus is circulating in the community, oseltamivir, a neuraminidase inhibitor, should be used for post-exposure prophylaxis in "at risk" patients aged 13 years or older, who are not protected by vaccination and who can begin prophylaxis within 48 hours.
展开▼
